Safer transfusions, better patient care. That’s our mission.

New Health Sciences seeks to bring about radical improvements in patient care through the acquisition, development, and commercialization of innovative technologies in transfusion medicine.

Spotlight

Quality Engineer New Health Sciences Awarded $3 Million NIH Grant to Commercialize Hemanext®

New Health Sciences, Inc. (NHSi), a medical technology company focused on innovations that improve transfusion therapy, today announced today that it has been awarded an SBIR Phase IIB Bridge Grant by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).  The award provides $3 million in funding over 3 years to complete the product development and clinical work required to commercialize Hemanext®, NHSi’s novel gas optimized storage system for donated red blood cells.

Read More >

News

NHSi Participation in Meeting Sponsored by Centro Nazionale Sangue

September 12th, 2016|Comments Off on NHSi Participation in Meeting Sponsored by Centro Nazionale Sangue

Recently, Dr. Tatsuro Yoshida, the Director of Research for New Health Sciences, […]

Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells

July 31st, 2016|Comments Off on Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells

The July issue of Blood includes an article published by New Health […]

Read All News >